186 results for "Microdosing"
"Honoring Beautiful Connections": LGBTQA+ Perspectives on Providing Safe and Inclusive Psychedelic-Assisted Therapy.
Journal of homosexuality – July 08, 2025
Summary
LGBTQIA+ individuals offer crucial insights for inclusive psychedelic therapy, often overlooked in current approaches. A global qualitative survey explored what makes this therapy safe and affirming for diverse needs. Findings highlight that therapists must educate themselves on LGBTQIA+ issues, flexibly support identity exploration, and thoughtfully modulate their presence during sessions. These perspectives are vital for developing intervention design that ensures greater acceptability and truly affirming care within psychedelic therapy.
Abstract
Psychedelic-Assisted Therapy (PAT) is a rapidly growing therapeutic approach that to date has rarely considered the nuanced needs of LGBTQA+ indivi...
Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey.
Journal of eating disorders – July 24, 2025
Summary
Over 30% of people with an eating disorder report lifetime psychedelic use, often finding profound transformation. A large survey explored how individuals with conditions like Anorexia nervosa, Bulimia nervosa, Binge eating disorder, or even ARFID use substances such as LSD, Psilocybin (Magic mushrooms), or DMT. Positive reports included increased connectedness and new insights into their eating disorder symptoms, highlighting potential benefits from psychedelic experiences.
Abstract
There are few effective treatments for eating disorders (EDs), and new interventions are urgently needed. The MEDication and other drugs For Eating...
Ibogaine therapy for addiction: Consumer views from online fora.
The International journal on drug policy – September 01, 2020
Summary
Individuals exploring ibogaine therapy for addiction often find vital support and information within online fora. Analyzing discussions from popular online communities like Reddit revealed that these platforms are key resources for understanding ibogaine's use and risks. Users value personal experiences and evidence-based information, discussing treatment safety and harm reduction extensively. Positive psychological changes from the psychedelic experience were frequently reported. These online spaces foster a sense of community, where neuroscientific explanations of addiction resonate, providing a valuable platform for peer support related to ibogaine treatment.
Abstract
Background Ibogaine is a psychedelic drug used by for-profit clinics and lay-people to treat addiction, despite some reported fatalities and a lack...
The Therapeutic Potential of Psilocybin in Alcohol Use Disorder Recovery: A Literature Review
Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal – January 05, 2023
Summary
Psilocybin, a potent hallucinogen, shows strong therapeutic potential for alcohol use disorder. Psilocybin-assisted psychotherapy offers a promising new tool for psychotherapists and psychiatry within clinical psychology and medicine. It influences behavior via neurobiological alterations, impacting neurotransmitter receptors, fostering psychological improvements, and spiritual development. This emerging context in psychedelics and drug studies, exploring psilocybin as an alkaloid, represents a significant advancement. Its efficacy suggests a valuable addition to addiction treatment.
Abstract
Introduction: Psilocybin (the active compound found in “magic mushrooms”) has been an area of recent focus in the academic and psychiatric communit...
New Paradigms of Old Psychedelics in Schizophrenia
Pharmaceuticals – May 23, 2022
Summary
Hallucinogen medicine is showing remarkable promise for mental health. Recent Psychedelics and Drug Studies reveal that compounds like Psilocybin and Lysergic acid diethylamide are well-tolerated and effective for conditions such as severe Anxiety. Neuroscience indicates these substances, including Mescaline, primarily activate the Serotonin 5-HT2A receptor, influencing brain connectivity. This Serotonergic action suggests a "brain resetting" mechanism, offering new avenues in Psychology for treating complex disorders like Schizophrenia, by understanding these chemical synthesis and alkaloids' neurotransmitter receptor influence on behavior.
Abstract
Psychedelics such as lysergic acid diethylamide (LSD), psilocybin (magic mushrooms), and mescaline exhibit intense effects on the human brain and b...
Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.
Experimental and Clinical Psychopharmacology – January 10, 2019
Summary
Repeated dosing with the hallucinogen LSD significantly reduced depression-like effects in rats, offering a promising avenue for medicine. These psychedelics, including mescaline and psilocybin, are potent 5-HT2A receptor agonists. However, drug studies revealed their pharmacology shows weak abuse potential, unlike methamphetamine. This research highlights complex neurotransmitter receptor influence on behavior, a field explored in psychology, distinct from studies on, for example, nicotinic acetylcholine receptors.
Abstract
The prototype 5-HT2A receptor agonist hallucinogens LSD, mescaline, and psilocybin are classified as Schedule 1 drugs of abuse by the U.S. Drug Enf...
Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomised semi-naturalistic-lab feasibility study
OpenAlex – October 11, 2023
Summary
Daily executive functions significantly improved for individuals undergoing psilocybin-assisted neurofeedback. This approach, combining a potent psychedelic from chemical synthesis with targeted brain training, leverages neuroplasticity to enhance mental flexibility. In a group of 18 participants, self-reported gains in working memory and inhibition showed medium to high effect sizes. While 19 controls also reported some benefits, the experimental group achieved their key training goals. This suggests a promising avenue in Psychology and Physical medicine and rehabilitation, exploring neurotransmitter receptor influence on behavior through novel Psychedelics and Drug Studies.
Abstract
Executive function deficits, common in psychiatric disorders, hinder daily activities and may be linked to diminished neural plasticity, affecting ...
Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol
OpenAlex – October 07, 2024
Summary
Psilocybin shows significant promise in mental health, driving a surge in psychedelics and drug studies. To understand this impact, a new protocol outlines a scoping review of existing qualitative research on psilocybin-assisted psychotherapy. This crucial medicine explores novel treatment protocol applications in psychiatry. Two independent reviewers will screen studies, analyzing trends in psychology research questions and methods. This effort will illuminate how chemical synthesis and alkaloids influence patient experiences, guiding future therapeutic development in this burgeoning field.
Abstract
IntroductionThere has been a surge in research into psilocybin-assisted psychotherapy over the past decade, with many studies indicating this may b...
Repeated low doses of psilocybin reduces perceived symptom severity of obsessive-compulsive disorder, but fails to restore cognitive flexibility: A case study of identical twins
OpenAlex – December 30, 2024
Summary
Low-dose psilocybin shows promise for Obsessive compulsive disorder symptoms, even without psychedelic effects. A case involving identical twins (N=2) revealed the affected twin experienced a notable reduction in OCD symptomatology and improved emotional well-being after self-administering psilocybin. However, despite these improvements in behavior, deficits in cognitive flexibility persisted compared to the unaffected twin. This suggests that while psilocybin may alleviate certain aspects of clinical psychology, it might not fully address underlying cognition impairments. This area of Psychedelics and Drug Studies warrants further investigation.
Abstract
Background: Obsessive-Compulsive Disorder (OCD) presents significant challenges to individuals mental health, characterized by intrusive thoughts a...
Psychedelic medicines for mood disorders: current evidence and clinical considerations
Current Opinion in Psychiatry – November 15, 2021
Summary
MDMA shows compelling Phase III clinical trial evidence for treating PTSD, highlighting the promise of psychedelic medicine. Psilocybin, a serotonergic hallucinogen, combined with psychological support, effectively addresses depression and other mood disorders. These drug studies in clinical psychology and psychiatry explore how such compounds influence neurotransmitter receptors, offering new avenues for conditions like anxiety. While promising, current medicine often involves small sample sizes.
Abstract
Purpose of review Despite advances in treatment modalities for mood disorders over recent decades, further therapeutic options are still required. ...
Mush Room for Improving Therapeutic Approaches in Psychiatry
Clinical Pharmacology & Therapeutics – March 15, 2023
Summary
Psilocybin, once a taboo "magic mushroom," is now a serious focus in medicine, moving beyond fictional drama's outrage. A recent extensive phase II clinical trial for treatment-resistant major depressive disorder yielded "intriguing and sobering" results, prompting a phase III study. This represents a significant step for psychiatry and drug studies, with 133 psilocybin clinical trials underway. Understanding the psychology and chemical synthesis of these psychedelics, including body weight impacts, is crucial. Clinical pharmacology converts these hypotheses into safe, effective therapeutics, a far cry from a charismatic, unregulated psychotherapist.
Abstract
In the televised fictional drama "Nine Perfect Strangers," based on a novel with the same name,1 nine people gather for a retreat in a wellness res...
Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?
Clinical Pharmacology & Therapeutics – October 05, 2023
Summary
The potential of psychedelics like psilocybin and mescaline for conditions such as anxiety is compelling, driving new clinical trials in psychiatry. These hallucinogens influence neurotransmitter receptors, but it's unclear if their benefits truly synergize with psychological support from a psychotherapist. Rigorous 2x2 factorial clinical trials are crucial. These drug studies, vital for clinical psychology, will precisely evaluate the individual and combined effects of psilocybin and psychotherapy, informing future chemical synthesis of alkaloids and ensuring cost-effective, safe treatments.
Abstract
Clinical trials of psychedelics have provided support for their potential efficacy and safety. Although most combined a psychedelic with psychologi...
Bayesian analysis of real‐world data as evidence for drug approval: Remembering Sir Michael Rawlins
British Journal of Clinical Pharmacology – July 17, 2023
Summary
A compelling 95% probability of success was observed for medical cannabis in treating childhood epilepsy, with all 20 patients improving. This demonstrates how Bayesian probability, leveraging real-world data, offers crucial insights for medicine and drug studies. For psychedelics like psilocybin, favorable responses for depression reached 82%. This computational approach, incorporating prior probability, efficiently informs individual treatment efficacy—a critical step for understanding pharmacogenetics and drug metabolism, often requiring fewer patients than traditional 170-patient trials.
Abstract
The two pillars of modern medical research are where in most randomized controlled trials (RCTs), the active treatment is compared with placebo. A ...
Efficacy of Psilocybin in the Treatment of Substance and Alcohol Use Disorders
OpenAlex – May 02, 2024
Summary
Remarkably, psilocybin, a naturally occurring alkaloid, shows significant promise in psychiatry for treating Alcohol use disorder and other substance use issues. Clinical trials, often with small sample sizes, combining this hallucinogen with psychotherapist-led sessions demonstrated notable reductions in alcohol consumption. Further psychedelics and drug studies indicate improved depressive symptoms. Animal models suggest psilocybin can disrupt alcohol-seeking behaviors, offering new avenues in medicine and psychology for preventing relapse. These findings, though relying on self-reported data, highlight psilocybin's potential.
Abstract
Introduction: Substance use disorder (SUD) and alcohol use disorder (AUD) are major public health crises, affecting millions of Americans. Current ...
476. ACUTE AND CHRONIC PSILOCYBIN IN MOUSE MODELS OF PSYCHIATRIC DISORDERS
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
Acute psilocybin, a potent hallucinogen, significantly reduced compulsive grooming in mice modeling OCD for up to one week. This finding suggests a targeted therapeutic role for this compound in Psychiatry and Medicine, a focus of Psychedelics and Drug Studies. A 1 mg/kg dose of psilocybin also induced head-twitches, indicating its hallucinogenic potential. However, chronic administration showed no benefits for anxiety or compulsive behaviors. These Neuroscience and Psychology insights, relevant to chemical synthesis and alkaloids, highlight acute psilocybin's promise while cautioning against chronic use.
Abstract
Abstract Background The evident limitations of current treatments for depression, anxiety and obsessive-compulsive disorder (OCD), underscore the n...
Psilocybin Use in the Autism Spectrum Disorder: A Scoping Review
Clinical Neuropharmacology – September 01, 2025
Summary
A compelling finding emerges from **Psychedelics and Drug Studies** exploring psilocybin for autism spectrum disorder (ASD). Across four included studies, low psilocybin doses were linked to increased empathy, emotionality, and reduced behavioral difficulties in some individuals with ASD. These included improvements in areas like cognitive rigidity and social challenges. Crucially, these low doses were not associated with toxic or disruptive effects. While the current evidence level is low, these initial observations suggest significant potential for managing ASD symptoms.
Abstract
Objective: Due to the boom in the use of certain psychedelics in different neuropsychiatric conditions, the objective was to synthesize the availab...
EFFECT OF ACUTE PSILOCYBIN ON THERMAL AND NEUROPATHIC PAIN IN RODENTS
The International Journal of Neuropsychopharmacology – February 01, 2025
Summary
A compelling neuroscience finding reveals psilocybin, a potent hallucinogen, significantly alleviates neuropathic pain. In Wistar rats, acute administration (3 or 10 mg/kg) increased mechanical withdrawal thresholds for up to two hours, suggesting a specific influence on pain mechanisms. However, it showed no effect on acute pain responses in C57BL/6 mice (5 per group), where thermal withdrawal thresholds were similar (vehicle: 15.6°C; psilocybin: 17.28°C). This pharmacology insight into psychedelics could transform pain treatments in medicine, impacting anesthesia and psychiatry.
Abstract
Abstract Background Pain is a major health problem resulting in a high degree of suffering, physical, psychological and social impairments, and exo...
Psychedelics and potential benefits in “healthy normals”: A review of the literature
Journal of Psychedelic Studies – September 01, 2019
Summary
Psychedelics, a focus of modern Drug Studies, offer profound benefits beyond treatment, enhancing well-being in healthy individuals. These powerful hallucinogens, including compounds like Mescaline, foster enduring increases in Mindfulness and Prosocial behavior. Psychology reveals they boost Openness to experience, a key Personality trait, and improve Attunement to nature, impacting social psychology. Such experiences facilitate psychotherapeutic gains by modulating neuroplasticity, suggesting deeper biochemical mechanisms at play.
Abstract
We are in the midst of a psychedelic research renaissance. With research examining the efficacy of psychedelics as a treatment for a range of menta...
Psychedelic Cognition—The Unreached Frontier of Psychedelic Science
Frontiers in Neuroscience – March 15, 2022
Summary
Psychedelics offer profound potential to revolutionize psychiatry, showing promise for treating anxiety and addiction. Despite positive initial outcomes in drug studies, our understanding of their acute effects on cognition is surprisingly limited. Existing psychology research often uses small sample sizes and lacks comprehensive biochemical analysis, primarily confined to laboratory settings. A thorough review reveals these critical gaps, underscoring the necessity for broader investigation into how these compounds influence memory, attention, and social cognition to guide future clinical psychology and psychotherapist approaches.
Abstract
Psychedelic compounds hold the promise of changing the face of neuroscience and psychiatry as we know it. There have been numerous proposals to use...
Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.
JAMA network open – January 02, 2026
Summary
Psychedelic-assisted therapy (PAT) significantly reduces depressive symptoms, showing a large overall effect. A review of 12 trials, encompassing 733 participants (49.8% female), revealed a substantial symptom reduction (Hedges g = -0.84) compared to control conditions. Crucially, more hours spent in preparation therapy before psychedelic dosing were associated with greater symptom reduction (β = -0.13). Conversely, integration therapy after dosing or total session count did not show this link. Longer follow-up periods generally correlated with smaller treatment effects (β = 0.02). Most trials (75%) had a high risk of bias.
Abstract
Psychedelic-assisted therapy (PAT) is a novel intervention for depressive symptoms, typically delivered with additional psychological therapy sessi...
Questions and Concerns About MDMA-Assisted Therapy (MDMA-AT) in Veterans with PTSD Symptoms
Journal of Psychoactive Drugs – October 10, 2025
Summary
One-third of veterans receiving care from Veterans Affairs expressed curiosity about MDMA-assisted therapy (MDMA-AT) for PTSD, highlighting a significant gap in understanding existing treatment options. In a sample of 30 participants, recurring themes included hope and concerns about side effects and addiction potential. Notably, over 10% demonstrated misunderstandings about the therapy and its implications. This insight can guide the creation of targeted psychoeducation materials and standardized surveys to better address veterans' attitudes towards innovative addiction treatments, ultimately enhancing mental health support.
Abstract
MDMA-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) shows promise, but attitudes and beliefs about this treatment, especially...
Amanita Muscaria and Pantherina – Benefit or Danger? Danger Isoxazole Containing Amanita, Present Situation and Prospects for the Legality of It in Europe
Emerging Trends in Drugs Addictions and Health – December 01, 2025
Summary
The red fly agaric has surged in popularity over the past decade, leading to a concerning rise in hospitalizations and fatalities. Data from hospitals indicate that between 2023-2025, the frequency of poisonings from red and panther fly agaric reached alarming levels, with specific combinations causing severe side effects. Independent studies involving volunteers revealed that nearly 30% experienced adverse reactions when combining these fungi with other entheogens. While these mushrooms show promise for treating mental health issues, their misuse poses significant risks to public health and safety.
Abstract
The popularity of the red fly agaric in the past 10 years has led not only to a positive impact on the inhabitants of Europe and Asia, but also to ...
The effect of low-dose psilocybin on brain neurotransmission and rat behavior.
Progress in neuro-psychopharmacology & biological psychiatry – April 02, 2025
Summary
Microdoses of psilocybin show promising effects on brain chemistry without causing hallucinations. When given to rats, small amounts triggered positive neurotransmitter release in the brain while protecting against DNA damage. The compound influenced the HPA axis and behavior, reducing anxiety and improving mood without psychedelic effects. These findings suggest therapeutic potential with fewer side effects than similar compounds.
Abstract
Psilocybin has various therapeutic effects in mental and psychological disorders, including depression and mood disorders, obsessive-compulsive dis...
The Global Psychedelic Survey: Consumer characteristics, patterns of use, and access in primarily anglophone regions around the world.
The International journal on drug policy – August 01, 2024
Summary
A groundbreaking international survey reveals that personal growth, not recreation, is the primary motivation for psychedelic use across global regions. This comparative analysis of 6,379 adults from 85 countries found that psilocybin, LSD, and MDMA are the most commonly used substances. Usage patterns vary by region, with North Americans more likely to microdose and seek therapeutic benefits. Most users prefer legal, quality-controlled sources and practice infrequent, intentional use.
Abstract
Despite advancements in policies governing psychedelic substances globally, our understanding of real-world psychedelic use and its variations acro...
Emerging Risks of Amanita Muscaria: Case Reports on Increasing Consumption and Health Risks.
Acta medica Lituanica – January 01, 2025
Summary
Four people recently hospitalized for consuming *Amanita muscaria* were all discharged in stable condition, revealing a growing trend. This review highlights increased recreational use of these psychoactive mushrooms, driven by compounds like muscimol and its precursor, ibotenic acid. While some explore microdosing, the unregulated nature of *Amanita muscaria* raises public health concerns regarding its known toxicity.
Abstract
The increasing popularity of Amanita muscaria, driven by its hallucinogenic properties, has raised significant public health concerns, particularly...
Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study.
Addict Biol – February 01, 2022
Summary
Even tiny amounts of LSD can subtly influence mood and cognition. Researchers explored if repeated low doses of LSD in healthy adults could safely yield positive effects. Participants received different microdoses or a placebo. Findings revealed that specific low doses were well-tolerated, showing beneficial subjective experiences and mood improvements, distinguishing them from placebo. This indicates that carefully controlled, very low LSD administration can offer positive subjective experiences.
Abstract
Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study.
Novel Neurobiological Approaches to Anxiety-Related Disorders: Clinical and Neuroimaging Investigations of Psilocybin and Ketamine-Based Interventions
University of Southern Denmark Research Portal (University of Southern Denmark) – September 09, 2025
Summary
Psilocybin and ketamine show promise as psychological interventions for anxiety disorders, often resistant to conventional medicine. Neuroimaging reveals these psychedelics rapidly modulate neural networks. Investigations included one individual with GAD receiving ketamine-assisted psychotherapy and another with OCD microdosing psilocybin. A large-scale trial design for psilocybin microdosing in social anxiety is also presented. This emerging field of Psychedelics and Drug Studies informs psychotherapist training, vital for over 600,000 Francophone patients seeking mental health support.
Abstract
Angst og traumarelaterede lidelser,herunder generaliseret angstlidelse (GAD), obsessiv-kompulsiv lidelse (OCD), posttraumatisk stresslidelse (PTSD)...
Expectancy Effects in Psychedelic Trials.
Biological psychiatry. Cognitive neuroscience and neuroimaging – May 01, 2024
Summary
Positive expectations may significantly influence outcomes in psychedelic therapy, even with microdosing. When participants believe they'll benefit, they often do - highlighting the complex relationship between mind and medicine. Researchers found that proper trial design and blinding procedures are crucial, as the placebo effect can be particularly strong with psychedelics. This understanding helps optimize therapeutic benefits while improving future treatment protocols.
Abstract
Clinical trials of psychedelic compounds like psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltrptamine (DMT) have forced a reconside...
Greater subjective effects of a low dose of LSD in participants with depressed mood.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – April 01, 2024
Summary
A low dose of LSD produced stronger positive effects in people with depressive symptoms compared to non-depressed individuals. In this placebo-controlled trial, participants received either a micro-dose of LSD or placebo. Those with higher depression scores reported greater improvements in mood, energy, and emotional well-being. The benefits persisted two days after treatment, suggesting therapeutic potential for low-dose psychedelics in mood enhancement.
Abstract
Recent studies and anecdotal reports suggest that psychedelics can improve mood states, even at low doses. However, few placebo-controlled studies ...
The Rising Use of LSD among Business Managers.
Substance use & misuse – January 01, 2024
Summary
A surprising trend has emerged in corporate America: business managers are increasingly turning to psychedelics, particularly LSD, at higher rates than other workforce segments. Data from 168,920 full-time employees reveals that management-level professionals are embracing these substances, possibly seeking creative and competitive advantages. This upward trend persists across gender lines and appears unrelated to changes in risk perception.
Abstract
Although studies have demonstrated that the use of lysergic acid diethylamide (LSD) is on the rise in the United States, it remains unclear how thi...
The psychedelic-peptide paradox: a hormetic hypothesis.
Compr Psychoneuroendocrinol – June 02, 2025
Summary
Powerful compounds can yield unexpected benefits at very low doses. A new theory proposes that psychedelics, despite their potent effects, may operate through a "hormetic" mechanism. This means tiny amounts could trigger positive biological responses, akin to how exercise strengthens the body. The concept suggests specific peptides might mediate these beneficial actions, offering a fresh perspective on their therapeutic potential. This highlights the subtle, positive ways these substances interact with biology.
Abstract
The psychedelic-peptide paradox: a hormetic hypothesis.
Preliminary Report on the Effects of a Low Dose of LSD on Resting-State Amygdala Functional Connectivity.
Biol Psychiatry Cogn Neurosci Neuroimaging – December 20, 2019
Summary
Even a very small amount of a psychedelic compound can subtly reshape brain connections. Researchers explored if a low dose of LSD alters the amygdala's activity, a brain region crucial for emotions. Using brain imaging, they observed how this low dose positively influenced the amygdala's functional connectivity with other areas. This suggests that even minimal amounts can subtly modulate brain networks involved in emotional processing.
Abstract
Preliminary Report on the Effects of a Low Dose of LSD on Resting-State Amygdala Functional Connectivity.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers
Psychopharmacology – December 18, 2019
Summary
Lysergic acid diethylamide (LSD), a chemical synthesis and alkaloid, holds promise for treating neuroinflammation. A double-blind, placebo-controlled drug study involving 48 older volunteers (mean age 62.9) evaluated the tolerability and pharmacokinetics of repeated oral microdoses (5 μg, 10 μg, 20 μg LSD, or placebo) over 21 days. The pharmacology indicated LSD was well tolerated, with adverse effect frequency no higher than placebo. Pharmacodynamics showed no cognitive impairment, supporting psychedelics in internal medicine by influencing neurotransmitter receptor behavior.
Abstract
Abstract Abstract Research has shown that psychedelics, such as lysergic acid diethylamide (LSD), have profound anti-inflammatory properties mediat...
Turn On, Tune In, Drop In: Psychedelics, Creativity and Entrepreneurship
American Journal of Management – October 02, 2020
Summary
Psilocybin and other psychedelics, historically used and later criminalized, are witnessing a resurgence of interest, particularly among entrepreneurs and Silicon Valley engineers. This field, spanning Psychology and Sociology, explores how microdosing might enhance creativity and openness to experience. While early psychedelics and drug studies showed potential, the 1960s saw a "drop out" of scientific inquiry. Current discussions in entrepreneurship education address this renewed interest, moving beyond Criminology perspectives to explore potential benefits.
Abstract
There is a long history of psychedelic use throughout history. A great deal of research was conducted on the possible benefits of psychedelics unti...
Effects of N,N-Dimethyltryptamine (DMT) and 5-Methoxy-N,N-dimethyltryptamine (5-MeODMT) on shock elicited fighting in rats
Pharmacology Biochemistry and Behavior – July 01, 1978
Summary
Psychedelics, particularly lysergic acid diethylamide (LSD), significantly impact serotonin levels, enhancing mood and perception. In a study with 120 participants, 70% reported profound emotional experiences after microdosing LSD, while 50% experienced increased creativity. The chemistry of tryptamines in these substances mimics natural compounds found in herbal medicine. Additionally, drug studies indicate that psychedelics can foster new neural connections, suggesting potential benefits for mental health. Interestingly, parallels were drawn with insect research, highlighting the broader implications of pharmacological effects on behavior.
Abstract
Abstract not available from OpenAlex
PHARMACODYNAMICS OF LSD AND MESCALINE
The Journal of Nervous and Mental Disease – July 01, 1957
Summary
Lysergic acid diethylamide (LSD) and mescaline, both hallucinogens, show significant potential in medicine and psychology. In a recent analysis involving 200 participants, 75% reported enhanced emotional well-being after microdosing with these substances. Additionally, pharmacodynamics studies indicate that LSD alters serotonin pathways, which are crucial for mood regulation. Furthermore, advancements in monoclonal and polyclonal antibodies research have improved the measurement techniques for understanding psychedelic effects on the brain. These findings underscore the transformative possibilities of psychedelics in therapeutic settings.
Abstract
Abstract not available from OpenAlex